The Technical Analyst
Alpha Tau Medical Ltd. [DRTS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Alpha Tau Medical Ltd. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.40% $2.49
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 173.48 mill |
| EPS: | -0.420 |
| P/E: | -5.93 |
| Earnings Date: | May 22, 2024 |
| SharesOutstanding: | 69.67 mill |
| Avg Daily Volume: | 0.0319 mill |
| RATING 2024-04-24 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.93 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.01x |
| Company: PE -5.93 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0365 (-98.53%) $-2.45 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.37 - 2.58 ( +/- 4.25%) |
| ATR Model: 14 days |
Forecast:
16:00 - $2.49
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.49
Forecast 2: 16:00 - $2.49
Forecast 3: 16:00 - $2.49
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.49 (-0.40% ) |
| Volume | 0.0028 mill |
| Avg. Vol. | 0.0319 mill |
| % of Avg. Vol | 8.81 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DRTS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Latest Press Releases
2024-03-25 08:50:00 - Press Release
Alpha Tau To Present At The Jefferies Radiopharma Innovation Summit
Jerusalem, march 25, 2024 (globe newswire) -- alpha tau medical ltd. ("alpha tau", or the “company”) (nasdaq: drts, drtsw), the developer of the innovative alpha-radiation cancer therapy alpha dart™, today announced that cfo raphi levy will present a corporate overview and update at the jefferies radiopharma innovation summit on april 11th, 2024.
2024-03-07 16:01:00 - Press Release
Alpha Tau Medical Announces Full Year 2023 Financial Results And Provides Corporate Update
- positive interim safety and feasibility data from pancreatic cancer study in montreal , with initial signs of potential dose response findings -
2024-02-26 08:30:00 - Press Release
Alpha Tau To Participate In Barclays 26th Annual Global Healthcare Conference
Jerusalem, feb. 26, 2024 (globe newswire) -- alpha tau medical ltd. ("alpha tau", or the “company”) (nasdaq: drts, drtsw), the developer of the innovative alpha-radiation cancer therapy alpha dart™, today announced that management will participate at the barclays 26th annual global healthcare conference on march 12th and 13th, 2024.
2023-12-20 09:15:00 - Press Release
Alpha Tau To Present At The 42nd Annual J.p. Morgan Healthcare Conference
- the overview presentation will review some of the company's recent achievements, including highly promising interim results from the company's pancreatic cancer safety and feasibility trial as well as robust long-term data analyzed across four clinical trials -
2023-11-29 08:30:00 - Press Release
Alpha Tau To Participate In Sidoti Small-cap Conference
Jerusalem, nov. 29, 2023 (globe newswire) -- alpha tau medical ltd. ("alpha tau", or the “company”) (nasdaq: drts, drtsw), the developer of the innovative alpha-radiation cancer therapy alpha dart™, today announced that management will present at the sidoti small-cap virtual conference on thursday, december 7th, 2023.
Latest News
2024-03-25 08:50:00 - GlobeNewsWire
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Radiopharma Innovation Summit on April 11th, 2024.
2024-02-26 08:30:00 - GlobeNewsWire
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate at the Barclays 26th Annual Global Healthcare Conference on March 12th and 13th, 2024.
2024-01-22 10:44:36 - Zacks Investment Research
Is Alpha Tau Medical (DRTS) Stock Outpacing Its Medical Peers This Year?
Here is how Alpha Tau Medical Ltd. (DRTS) and Regeneron (REGN) have performed compared to their sector so far this year.
2024-01-08 11:17:43 - Zacks Investment Research
Best Momentum Stocks to Buy for January 8th
AKYA, DRTS and TRUP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.
2024-01-08 07:31:19 - Zacks Investment Research
New Strong Buy Stocks for January 8th
TIMB, AKYA, DRTS, TRUP and QSG have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.
2023-12-20 09:15:00 - GlobeNewsWire
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- The overview presentation will review some of the Company's recent achievements, including highly promising interim results from the Company's pancreatic cancer safety and feasibility trial as well as robust long-term data analyzed across four clinical trials -
2023-11-22 11:18:49 - Zacks Investment Research
Down -20.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Alpha Tau Medical Ltd. (DRTS)
Alpha Tau Medical Ltd. (DRTS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
2023-08-24 08:00:00 - GlobeNewsWire
Alpha Tau Medical to Participate in September Investor Conferences
JERUSALEM, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences.
2023-08-02 09:00:00 - GlobeNewsWire
Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023
JERUSALEM, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will present at the Emerging Growth Conference on August 9th, 2023.
2023-05-24 16:01:00 - GlobeNewsWire
Alpha Tau Medical to Participate in June Investor Conferences
JERUSALEM, May 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences.